Low Molecular Weight Heparin Vs Direct Oral Anticoagulants (Apixaban, Edoxaban and Rivaroxaban) for the Treatment of Cancer Associated Thrombosis: A Cost- Effective Analysis

被引：0
|
作者：
Gulati, Shuchi [1 ]
Elsisi, Zizi [2 ]
Deoghare, Smruti [2 ]
Eckman, Mark [2 ]
机构：
[1] Univ Cincinnati, Vontz Ctr Mol Studies, Cincinnati, OH USA
[2] Univ Cincinnati, Cincinnati, OH USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124756
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
328
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Low-molecular weight heparin or direct oral anticoagulants for the treatment of cancer associated thrombosis. Are we at the crossroad?
    Meyer, Guy
    THROMBOSIS RESEARCH, 2019, 173 : 156 - 157
  • [2] Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis
    Kaidireyahan Wumaier
    Wenqian Li
    Naifei Chen
    Jiuwei Cui
    Thrombosis Journal, 19
  • [3] Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis
    Wumaier, Kaidireyahan
    Li, Wenqian
    Chen, Naifei
    Cui, Jiuwei
    THROMBOSIS JOURNAL, 2021, 19 (01)
  • [4] Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis
    Kang, Wei
    Peng, Kuan
    Yan, Vincent K. C.
    Al-Badriyeh, Daoud
    Lee, Shing Fung
    Yiu, Hei Hang Edmund
    Wei, Yue
    Li, Silvia T. H.
    Ye, Xuxiao
    El Helali, Aya
    Lam, Ka On
    Lee, Victor H. F.
    Wong, Ian C. K.
    Chan, Esther W.
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2024, 17 (01)
  • [5] Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil
    Lopes, Danilo G.
    Tamayo, Arturo
    Schipp, Bernhard
    Siepmann, Timo
    THROMBOSIS RESEARCH, 2020, 196 : 4 - 10
  • [6] Cancer-Associated Thrombosis and Bleeding Risk in Gastrointestinal Malignancies with Apixaban and Rivaroxaban Compared to Low Molecular Weight Heparin
    Houghton, Damon E.
    Bott-Kitslaar, Dalene M.
    Vargas, Emily
    Hodge, David O.
    Lang, Teresa R.
    Peterson, Lisa
    Casanegra, Ana I.
    McBane, Robert D.
    Wysokinski, Waldemar E.
    Froehling, David A.
    BLOOD, 2018, 132
  • [7] Safety and Efficacy of Direct Oral Anticoagulants vs Low Molecular Weight Heparin for Treatment of Venous Thromboembolism in Patients With Cancer
    Singh, Sahib
    Tantry, Udaya
    Bliden, Kevin
    Gurbel, Paul
    CIRCULATION, 2023, 148
  • [8] Comparison of Direct Oral Anticoagulants Versus Low-Molecular-Weight-Heparins for the Treatment of Cancer Associated Thrombosis
    Phelps, Megan K.
    Wiczer, Tracy E.
    Erdeljac, H. Paige
    Van Deusen, Kelsey R.
    Porter, Kyle
    Phillips, Gary
    Wang, Tzu-Fei
    BLOOD, 2016, 128 (22)
  • [9] Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus low molecular-weight heparin (LMWH) for the treatment of cancer associated thrombosis (CAT)
    Li, A.
    Manohar, P.
    Garcia, D.
    Lyman, G.
    Steuten, L.
    HAEMOPHILIA, 2019, 25 : 39 - 40
  • [10] Oral anticoagulants vs. low molecular weight heparin
    Mesters, RM
    INTERNIST, 2000, 41 (08): : 766 - 767
12345